Animal model
OwnerSusan Clare Stanford, Hugh Gurling +1inventors
InventorsSusan Clare Stanford, Hugh Gurling, Steven Hunt
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a NK1−/− animal as a model for attention deficit hyperactivity disorder and related conditions, to markers for those conditions and to methods of treating such conditions.
Claims28
(canceled)
(canceled)
The method according to claim 6 or 7, wherein the animal is a non-human animal.
A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliverate self-harm or -injury, or suicidality, comprising:
- contacting a test compound with a cell, tissue, or organ from an NK1−/− animal or a NK1−/− cell or a tissue or organ made up of such cells and determining effects of the test compound.
A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury, or suicidality comprising;
- administering a test compound to a NK1−/− animal or to an animal treated with an antagonist to substance P receptor;
- and
- determining effects on behavior of the animal.
A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self harm or injury or suicidality comprising:
- administering a test compound to a NK1−/− animal or to an animal treated with an antagonist to substance P receptor;
- and
- determining changes in neurotransmitter function in brain of the animal.
(canceled)
A method of determining a predisposition of a subject to ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
- identifying a polymorphism in an NK1 gene or a region flanking that gene in a sample obtained from that subject, wherein the polymorphism is a marker for ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality.
A method of determining a predisposition of a subject to ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
- identifying in a sample obtained from the subject a peptide encoded by, or an RNA molecule complementary to, an NK1−/− gene comprising a polymorphism, wherein the peptide is not encoded by, and the RNA molecule is not complementary to a wild-type NK1 gene, wherein the polymorphism is associated with ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality.
A transgenic animal that comprises an exogenous NK1 gene.
(canceled)
(canceled)
A method of treating ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
- administering a pharmaceutical composition comprising a vector comprising a wild-type NK1 gene to a subject in need thereof.
(canceled)
(canceled)
A method of identifying a candidate compound for use in the treatment of ADHD, alcohol addiction, dyspraxia, conduct disorder, self-harm or -injury, or suicidality, comprising:
- testing for
- a compound that binds to a NK1 gene product, intracellular proteins or portions of proteins that interact with a NK1 gene product;
- a compound that interferes with the interaction of a NK1 gene product with intracellular proteins;
- or
- a compound that modulates level of NK1 gene expression and/or level of NK1 gene product activity;
- and
- identifying the compound as a candidate for treating ADHD, alcohol addiction, dyspraxia, conduct disorder, self-harm or -injury, or suicidality.
Dependencies are inferred from the claim text.